S&P 5007,691▲ 0.41%Nasdaq26,431▲ 1.11%Dow Jones51,966▼ 0.07%Nasdaq 10029,529▲ 1.17%VIX18.44▼ 7.75%US Dollar101.97▲ 0.13%Gold spot4,165▲ 0.21%WTI spot101.91▲ 1.04%
London Exchange · UK · Updated after 19 Oct 2026 close

Vertex Pharmaceuticals Inc.

0QZU · London Exchange · prices in USD
USD 505.04▲ +5.37 (1.07%)
Research reportHistorical data

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that discovers and develops medicines for serious diseases. Its main business is treating cystic fibrosis with a family of oral drugs that target the underlying protein defects caused by the disease. It also develops and sells gene-editing therapies for blood disorders and has medicines for pain. Its customers are patients, physicians and healthcare systems, mainly in North America, Europe and other markets where its products are approved.

Vertex Pharmaceuticals Inc. trades under the code 0QZU on the London Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

69/ 100
Market X-Ray · price-based
Fair price profile
Ranks #605 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
71/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average5.8%
From 52-week high-9.4%
MomentumStrong
71/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return5.3%
6-month return15.6%
12-month, skipping last month19.1%
Stability (higher is calmer)Strong
75/100
Calmer than most: low volatility and shallow drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)28.8%
Worst drawdown, 1 year (smaller is calmer)-15.8%
LiquidityFair
51/100
Moderate trading activity.
See the numbers →
Avg daily value traded0.90M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
Price trend
Above 200-day, below 50-day
Versus its 50- and 200-day averages
52-week range
403.16 – 577.24
Price is 59% of the way up
Returns
+5.3% 3m · +18.4% 1y
Price returns, dividends not included
RSI (14)
47
Neutral zone

Price chart

52-wk range 403.16 – 577.24 Daily closes, split-adjusted

Signals

50-day average523.34
200-day average477.14
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)19.83

Technical summary

Daily
Neutral
6 bullish · 4 neutral · 6 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10503.4Bullish
EMA 10504.6Bullish
SMA 20510.4Bearish
EMA 20508.8Bearish
SMA 50523.3Bearish
EMA 50510.9Bearish
SMA 100499.1Bullish
EMA 100500.2Bullish
SMA 200477.1Bullish
EMA 200482.9Bullish
Oscillators (daily)
RSI (14)46.66Neutral
MACD (12, 26)-5.18Bearish
Momentum (12)-0.66Bearish
Stochastic %K (14)44.52Neutral
Williams %R (14)-55.48Neutral
CCI (20)-69.53Neutral
Pivot points (classic, last session)
S3
479.2
S2
486.3
S1
495.7
Pivot
502.8
R1
512.2
R2
519.3
R3
528.7
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in USD. Educational only, not financial advice.